3-7 February 2008│Boston, Massachusetts
Coverage of Microbicides at CROI
The 15th Conference on Retroviruses and Opportunistic Infections (CROI) featured preventive, basic, and clinical research of relevance and importance to the microbicide and allied communities. The Alliance for Microbicide Development compiled microbicide-related science and news from the conference. Read More [insert link to: 6.4.2.5]
Conference Information
Website: http://www.retroconference.org/
| Important Dates |
| Abstract Submission |
10 October 2007 |
| Early Registration |
26 November 2007 |
| General Registration |
10 January 2008 |
| Conference |
3-7 February |
Program, Abstracts & Speakers
Program at-a-Glance
Browse Program & Search Abstracts
View Webcasts & Podcasts
Overview
The Conference on Retroviruses and Opportunistic Infections (CROI) is a yearly conference sponsored by the Foundation for Retrovirology and Human Health in collaboration with the Centers for Disease Control. The mission of CROI is to provide a forum for basic scientists, clinical investigators, and global health personnel to present, discuss, and critique their investigations into the epidemiology and biology of human retroviruses and the diseases they produce with the ultimate goal of translating laboratory and clinical research into progress against the AIDS epidemic. The conference will cover:
Track I: Basic Science (including Vaccines)
Immunology, Vaccines (Preventive)-Preclinical, Virology (including other Retroviruses), Pathogenesis (including Host Genetics), Neuropathogenesis and Neurologic Complications, Antiretroviral Therapy-Preclinical, Vaccines (Preventive)-Clinical Trials, Therapeutic Vaccines and Immune-Based Therapies (including Cytokine Therapy), and Primary/Acute Infection
Track II: Clinical Research and Therapy
Adult Antiretroviral Therapy-Clinical-Randomized Trials, Adult Antiretroviral Therapy-Clinical-Observational Studies, Clinical Pharmacology, HIV Drug Resistance (including Molecular Mechanisms, Clinical Implications, and Epidemiology of HIV Drug Resistance), Adult Antiretroviral Therapy-Complications, Opportunistic Infections (including Tuberculosis), Hepatitis Virus Co-Infections (e.g., HBV, HCV), AIDS-Related Malignancies (e.g., Lymphoma and Kaposi's Sarcoma), Pediatrics/Adolescents, Maternal/Fetal, HIV in Women/Women's Health, and Novel Diagnostic Technologies and New Monitoring Tools
Track III: Epidemiology and Prevention
Epidemiology of HIV Infection (excluding Epidemiology of HIV Drug Resistance), Molecular Epidemiology: Distribution and Diversity of Retroviruses (excluding Epidemiology of HIV Drug Resistance), Epidemiology of Sexually Transmitted Diseases other than HIV, and Prevention Studies (including Microbicides and Behavioral Interventions)
Track IV: Global Response to AIDS
Research on Delivery of Care in Developing Countries (including Operational Research and Implementation)
